Resumption of trastuzumab in patients with disease recurrence after (Neo-) adjuvant anti-HER2-therapy in patients with HER2-positive breast cancer

Lars Christian Hanker^*, Frank Förster, Jan Schröder, Andrea Grafe, Thomas Hitschold, Tobias Hesse, Claus Richard Lattrich, Achim Rody

^*Corresponding author for this work